Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study

Gatske M. Nieuwenhuyzen-de Boer*, Malika Kengsakul, Ingrid A. Boere, Helena C. van Doorn, Heleen J. van Beekhuizen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

31 Downloads (Pure)


Background: Patients with unresectable disease during cytoreductive surgery (CRS) for advanced-stage ovarian cancer are underreported. Knowledge of treatment and survival after surgery is limited. The aim of this study is to address the knowledge gap about postoperative treatment and survival of patients whose surgery was abandoned due to unresectability after abdominal exploration. Methods: Women with FIGO stage IIIB-IV epithelial ovarian cancer whose disease was considered to be unresectable during surgery were included in this prospective study, a post hoc analysis of the PlaComOv study. The unresectable disease was defined as the inability to achieve at least suboptimal CRS without attempted CRS after careful inspection of the entire abdomen. Preoperative clinical data, perioperative findings, postoperative treatment and survival data were analyzed. Results: From 2018 to 2020, 27 patients were included in this analysis. Treatment ranged from the cessation of treatment to one or several lines of chemotherapy with or without maintenance therapy. The median overall survival was 16 (IQR 5–21) months (95%CI 14–18). At 24 months of follow-up, four patients (15%) were alive. Conclusions: This study indicated a two-year survival of 15%. Optimal treatment strategies in terms of survival benefits are still ill-defined. Further study of this specific group of patients is warranted. We advocate an (inter)national registry of patients with unresectable cancer and comprehensive follow-up.

Original languageEnglish
Article number72
Issue number1
Publication statusPublished - 22 Dec 2022

Bibliographical note

Funding Information:
Data were collected in The PlaComOv study. This randomized controlled trial is funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805.

Publisher Copyright:
© 2022 by the authors.


Dive into the research topics of 'Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study'. Together they form a unique fingerprint.

Cite this